Chandrasekhar Abbineni

39-40 KIADB Industrial Area Electronic City Phase II, Hosur Road, 560 100
Bengaluru, KA, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Exploration of non-hydroxamate based quinoline analogues as HDAC8 inhibitors.

Exploration of non-hydroxamate based quinoline analogues as HDAC8 inhibitors.

Journal: RSC advances

Published: July 09, 2026

Targeted HDAC8 inhibition with non-hydroxamate [1,2,4]triazolo[4,3-a] quinoline compounds.

Targeted HDAC8 inhibition with non-hydroxamate [1,2,4]triazolo[4,3-a] quinoline compounds.

Journal: Scientific reports

Published: April 04, 2025

Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Journal: Nature

Published: April 22, 2024

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 01, 2024

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Journal: bioRxiv : the preprint server for biology

Published: March 11, 2024

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.

Journal: bioRxiv : the preprint server for biology

Published: February 08, 2024

Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.

Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.

Journal: Cancer cell

Published: December 05, 2023

Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders.

Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders.

Journal: Bioorganic & medicinal chemistry letters

Published: August 04, 2021

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Journal: Nature

Published: March 17, 2021

Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists.

Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: September 03, 2014

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: part 2.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: part 2.

Journal: Bioorganic & medicinal chemistry letters

Published: January 22, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026